These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28753810)

  • 41. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
    Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.
    Moschini M; Sharma V; Zattoni F; Boorjian SA; Frank I; Gettman MT; Thompson RH; Tollefson MK; Kwon ED; Karnes RJ
    J Urol; 2016 Jun; 195(6):1773-8. PubMed ID: 26723866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
    Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
    BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
    Budäus L; Isbarn H; Tennstedt P; Salomon G; Schlomm T; Steuber T; Haese A; Chun F; Fisch M; Michl U; Heinzer H; Huland H; Graefen M
    BJU Int; 2012 Dec; 110(11):1714-20. PubMed ID: 22520619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients.
    Huang QX; Xiao CT; Chen Z; Lu MH; Pang J; Di JM; Luo ZH; Gao X
    Asian J Androl; 2018; 20(1):56-61. PubMed ID: 28382925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience.
    Leyh-Bannurah SR; Dell'Oglio P; Zaffuto E; Briganti A; Schiffmann J; Pompe RS; Tilki D; Heinzer H; Graefen M; Karakiewicz PI; Budäus L
    Eur Urol Focus; 2019 Jul; 5(4):568-576. PubMed ID: 29129756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Strand SH; Bavafaye-Haghighi E; Kristensen H; Rasmussen AK; Hoyer S; Borre M; Mouritzen P; Besenbacher S; Orntoft TF; Sorensen KD
    Int J Cancer; 2019 Dec; 145(12):3445-3452. PubMed ID: 31125115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients.
    Saemundsson A; Xu LD; Meisgen F; Cao R; Ahlgren G
    Prostate; 2023 Sep; 83(12):1133-1140. PubMed ID: 36988135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis.
    Meurs P; Galvin R; Fanning DM; Fahey T
    BJU Int; 2013 Mar; 111(3):427-36. PubMed ID: 22882877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.
    Zhao SG; Chang SL; Spratt DE; Erho N; Yu M; Ashab HA; Alshalalfa M; Speers C; Tomlins SA; Davicioni E; Dicker AP; Carroll PR; Cooperberg MR; Freedland SJ; Karnes RJ; Ross AE; Schaeffer EM; Den RB; Nguyen PL; Feng FY
    Lancet Oncol; 2016 Nov; 17(11):1612-1620. PubMed ID: 27743920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
    Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
    Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
    Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.
    Hernández Hernández C; Kim Lee D; Sanchez Pérez M; Escobar SH
    Clin Genitourin Cancer; 2019 Jun; 17(3):e645-e649. PubMed ID: 31097389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.